Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments

Kristopher J. Hult

NBER Working Paper No. 23900
Issued in October 2017
NBER Program(s):Health Care, Health Economics, Productivity, Innovation, and Entrepreneurship

Individuals respond to pharmaceutical treatments differently due to the heterogeneity of patient populations. This heterogeneity can make it difficult to determine how efficacious or burdensome a treatment is for an individual patient. Personalized medicine involves using patient characteristics, therapeutics, or diagnostic testing to understand how individual patients respond to a given treatment. Personalized medicine increases the health impact of existing treatments by improving the matching process between patients and treatments and by improving a patient's understanding of the risk of serious side effects. In this paper, I compare the health impact of new treatment innovations with the potential health impact of personalized medicine. I find that the impact of personalized medicine depends on the number of treatments, the correlation between treatment effects, and the amount of noise in a patient's individual treatment effect signal. For multiple sclerosis treatments, I find that personalized medicine has the potential to increase the health impact of existing treatments by roughly 50 percent by informing patients of their individual treatment effect and risk of serious side effects.

download in pdf format
   (539 K)

email paper

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w23900

Published: Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments, Kristopher J. Hult. in Economic Dimensions of Personalized and Precision Medicine, Berndt, Goldman, and Rowe. 2019

Users who downloaded this paper also downloaded* these:
Angrist, Caldwell, and Hall w23891 Uber vs. Taxi: A Driver’s Eye View
Boyer, De Donder, Fluet, Leroux, and Michaud w23918 Long-Term Care Insurance: Knowledge Barriers, Risk Perception and Adverse Selection
Chandra, Garthwaite, and Stern w24026 Characterizing the Drug Development Pipeline for Precision Medicines
Persson w23823 Attention Manipulation and Information Overload
Murphy, Scott-Clayton, and Wyness w23888 The End of Free College in England: Implications for Quality, Enrolments, and Equity
NBER Videos

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email:

Contact Us